Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Direct Acting Antiviral Agents”

150 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 150 results

Not applicableUnknownNCT06325826
What this trial is testing

The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs

Who this might be right for
Hepatocellular Carcinoma
Egyptian Liver Hospital 500
Not applicableStudy completedNCT02581020
What this trial is testing

The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects

Who this might be right for
Hepatitis C Virus
AbbVie 344
Post-approval studies (Phase 4)Study completedNCT02938013
What this trial is testing

DeLIVER: Direct Acting Antiviral Effects on the Liver

Who this might be right for
HCV CoinfectionLiver DiseaseHIV
Johns Hopkins University 15
Not applicableUnknownNCT04063839
What this trial is testing

HCV Treatment in a Low-threshold Clinic

Who this might be right for
Hepatitis CSubstance Use Disorders
University Hospital, Akershus 300
Post-approval studies (Phase 4)Study completedNCT03961828
What this trial is testing

Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus

Who this might be right for
Beta-ThalassemiaHepatitis C
Tanta University 50
Not applicableStudy completedNCT01457755
What this trial is testing

Gilead Sustained Virologic Response (SVR) Registry

Who this might be right for
Hepatitis C, Chronic
Gilead Sciences 6,625
Not applicableUnknownNCT05376943
What this trial is testing

Possible Differences in HCC Course Depending on DAA Treatment

Who this might be right for
Carcinoma, HepatocellularHepatitis C Virus Infection, Response to Therapy ofDrug Effect+3 more
Medical University of Warsaw 100
Large-scale testing (Phase 3)Study completedNCT01979939
What this trial is testing

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

Who this might be right for
Hepatitis C
Bristol-Myers Squibb 416
Testing effectiveness (Phase 2)Study completedNCT01441180
What this trial is testing

GS-7977 With Ribavirin for Hepatitis C (SPARE)

Who this might be right for
Hepatitis C
National Institute of Allergy and Infectious Diseases (NIAID) 60
Post-approval studies (Phase 4)Study completedNCT03537196
What this trial is testing

DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)

Who this might be right for
Hepatitis CDrug UseViral Hepatitis C
ANRS, Emerging Infectious Diseases 979
Testing effectiveness (Phase 2)Study completedNCT02413593
What this trial is testing

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection

Who this might be right for
Hepatitis C Virus Infection
Gilead Sciences 111
Post-approval studies (Phase 4)Study completedNCT02064049
What this trial is testing

Surveillance and Treatment of Prisoners With Hepatitis C

Who this might be right for
Hepatitis C
Kirby Institute 3,692
Not applicableLooking for participantsNCT03685045
What this trial is testing

ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings

Who this might be right for
Hepatitis C
Kirby Institute 6,000
Large-scale testing (Phase 3)Study completedNCT02487030
What this trial is testing

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection

Who this might be right for
Hepatitis C Virus Infection
Gilead Sciences 255
Not applicableStudy completedNCT02648022
What this trial is testing

Integrated Care for Patients With High Risk Substance Use and Psychiatric Disorder With Chronic Direct Acting Antiviral Treatment

Who this might be right for
Hepatitis CDepressionPTSD+2 more
VA Office of Research and Development 83
Not applicableUnknownNCT02102451
What this trial is testing

Control and Elimination Within Australia of Hepatitis C From People Living With HIV

Who this might be right for
Hepatitis CHIVHIV-HCV Coinfection
Kirby Institute 492
Not applicableUnknownNCT01944527
What this trial is testing

Use of Direct-acting Antiviral to Treat HCV Recurrence After Liver Transplantation (ANRSCO23CUPILT) Infection

Who this might be right for
HCV RecurrenceLiver TransplantationDirect-acting Antiviral Agents
ANRS, Emerging Infectious Diseases 699
Not applicableUnknownNCT04251572
What this trial is testing

HCV Reinfection After DAA Therapy in PWID in Belgium

Who this might be right for
Hepatitis C Virus Infection, Response to Therapy ofDrug Use
Hasselt University 100
Testing effectiveness (Phase 2)UnknownNCT03261349
What this trial is testing

Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma

Who this might be right for
Indolent Lymphoma
National Taiwan University Hospital 21
Large-scale testing (Phase 3)Study completedNCT01604850
What this trial is testing

Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)

Who this might be right for
Chronic Hepatitis C
Gilead Sciences 202
Next Page